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Abstract: Bioinorganic chemists aspire to achieve the same 
exquisite and highly controlled inorganic chemistry, featured in 
Biology. An exciting mimetic approach involves the use of 
miniature artificial protein scaffolds designed de novo (often 
based on the coiled coil (CC) scaffold), for reproducing native 
metal ion sites and their function. Recently, there is increased 
interest, instead, in the design of xeno-metal sites within CC 
assemblies. This involves incorporating either non-biological 
metal ions, cofactors or non-proteinogenic amino acid ligands, 
for metal ion coordination, whilst retaining a minimal CC protein 
scaffold. Using this approach, one should be able to create 
functional designs with unique and unusual properties, which 
combine the advantages of both biology and ‘traditional’ non-
biological inorganic chemistry. It is the recent progress with 
respect to the design of xeno-metallo CCs which will be 
discussed in this focus review.  
1. Introduction  
It has been estimated that roughly a third of all native proteins 
contain metal ions which are essential for their function,[1] 
making the study of metalloproteins an attractive and worthwhile 
goal. The ability to artificially replicate challenging metal ion sites, 
both structurally and functionally, as well as recreating the 
exquisite bioselectivity and control displayed in biology, is one of 
the principle challenges of bioinorganic chemistry.  
This challenge has often been addressed through the 
synthesis of small molecule complexes, which resemble the 
biological metal ion site of interest. However, in some cases, 
small molecule complexes are unable to reproduce the 
chemistry of these sites, highlighting the importance of the 
protein scaffold. De novo peptide design can sometimes be 
adopted to mimic biology, and resulting miniature protein folds 
can be used to elucidate important structure-function 
relationships.[2] This approach has been successfully expanded 
to the de novo design of mimetic metallopeptides, yielding some 
state-of-the-art mimics,[3] and represents an exciting opportunity 
to bridge the gap between small synthetic inorganic complexes 
and complex native metalloproteins.  
In view of the above, it is thus also attractive to explore the 
coordination of xeno-metals, metals with no known biological 
role, as well as the introduction of other non-biological features, 
such as cofactors or non-proteinogenic amino acids, in to the 
design.[4] These hybrids could couple the diverse array of 
chemistry afforded by non-biological metal ion complexes, with 
the enormous benefits associated with the use of proteins as 
ligands for metal ions. As well as providing a sophisticated 
scaffold that can be used to delicately tune the properties of 
the metal ion, proteins can act as multidentate chelating 
ligands, providing spatial fixation and rigidity, and serve as a 
medium with well-defined dielectric properties. Ultimately, it is 
our belief that this approach will realize the true potential of 
bottom-up synthetic biology with respect to inorganic chemistry, 
yielding new metalloprotein hybrids (here we will focus on the 
CC motif) with novel properties. This focus review, which is far 
from exhaustive, will feature some key examples to illustrate 
this topic. The interested reader is directed to more 
comprehensive reviews on metallopeptide design.[5]  
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2. Xeno-metals 
Although metal ions are essential for many biological processes, 
Nature selects from a rather limited range.  Contrast this with the 
inorganic chemists’ toolbox, which has the breadth of elements 
across the Periodic Table to choose from, and consequently the 
potential to develop systems with a much more diverse range of 
properties and potential applications. This section focuses on 
some key examples where xeno binding sites, inspired by non-
biological Inorganic Chemistry, have been engineered into a CC 
scaffold. 
2.1. Lanthanides 
One class of xeno-metals (with only a single example of a 
biological role reported[6]) are the lanthanide ions. Having a 
similar size and bonding preference, Ln(III) ions are often 
capable of substituting Ca(II) sites to yield Ln(III) 
metallopeptides, in which the attractive photophysical and 
magnetic properties of the Ln(III) can be exploited.[7] Of 
relevance to this focus review, is the early work by Hodges and 
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co-workers[8] who reported the de novo design of a two stranded 
CC, bridged by a disulphide bond (owing to Cys residues in 
position two), for Ln(III) coordination. In the apo form the inter-
helical ionic repulsions across the dimer interface, between 
negatively charged carboxylic groups in the i and i’+5 positions 
(e and g sites), prevent peptide folding. However, Ln(III) binding 
to these glutamic acid (Glu, E) residues, neutralizes the 
repulsive charges and instead bridges the two Glu, triggering CC 
formation. Only a modest increase in folding was observed, due 
to the Ln(III) affinity for the site being relatively weak.[8b] A 
subsequent study using the non-proteogenic amino acid, γ-
carboxyglutamic acid (Gla, see section 3.1), in place of Glu, led 
to both a greater Ln(III) affinity and associated increase in 
folding.[7e]  
The first report of a Ln(III) site generated within a CC interior, 
involved the use of the non-proteinogenic Gla,[7e] and again 
focused on how Ln(III) coordination induced CC formation. 
Whilst Ln(III) binding was achieved, no detailed analysis of 
coordination chemistry was reported. More recently, we reported 
the design of a Ln(III) binding site within a CC interior using 
natural asparagine (Asn, N) and aspartic acid (Asp, D) residues 
(Figure 1). All Ln(III) ions tested (including Tb(III), Gd(III), Ce(III), 
Nd(III), Eu(III), Dy(III), Er(III) and Yb(III)) were found to bind.[9] 
Furthermore, we interrogated the coordination chemistry, and 
despite finding no evidence of inner sphere water, often 
assumed to be a prerequisite for Gd(III) MRI contrast agents, the 
Gd(III) CC, the first ever to be reported, displayed superior MRI 
relaxivity than the clinically employed Dotarem.[9] This example 
illustrates how a xeno-metal can be introduced, so that the 
resulting metallo-CC can be explored for a non-biological 
application, in this case medical imaging. 
 
Figure 1. Pymol model of a designed Ln(III) binding site within the 
hydrophobic core of a three-stranded CC. Shown are the main chain atoms 
represented as helical ribbons (green), the Asn, Asp and Trp side chains in 
stick form (oxygen in red and nitrogen in blue), and the Ln(III) ion as a grey 
sphere.[9] 
2.2. Uranyl  
To the best of our knowledge, the only actinide so far to be 
coordinated to a CC is uranium. Uranyl (UO22+), the predominant 
aerobic form of uranium, is present at a relatively high 
concentration in seawater. Whilst the vast array of metals with a 
similar size and charge to uranyl make it difficult to sequester 
effectively, a helical bundle has been engineered to selectively 
bind the uranyl with femtomolar affinity, and unprecedented 
selectivity (Figure 2).[10] A pentagonal bipyramidal binding site 
was computationally designed into the interior of a three-helical 
bundle, and has been verified experimentally from the crystal 
structures of both the apo and uranyl-bound forms (see Figure 
2).[10] The fact that a protein can be designed to display such 
impressive selectivity for a xeno-metal, is an exciting 
achievement for the community. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pymol image of a) the designed uranyl bound helical bundle; b) the 
uranyl ion binding pocket showing the pentagonal bipyramidal geometry. The 
main chain is shown as a helical ribbon (green), with the uranyl ion 
represented as a) spheres or b) in stick form (uranium in light blue and oxygen 
in red), the binding residues Asp68, Arg71 and Glu17 are also shown in stick 
form (nitrogen atoms in blue). Based on PDB code 4FZP.[10] 
2.3. Rhodium  
Ball and co-workers have extensively investigated dirhodium 
metallopeptides for catalysis,[11] in an effort to couple the 
catalytic activity of Rh(II) complexes, to the selectivity commonly 
encountered in enzymes, so as to achieve reactivity inaccessible 
to traditional transition metal catalysts.[11] Rh(II) carboxylates, 
bound through peptide Glu and Asp side chains, were found to 
be stable and catalytically active in water.[11b] Furthermore, by 
careful design of the peptide component, specifically the use of 
CC domains, designed dirhodium peptides were able to couple 
molecular recognition with catalytic activity, so as to allow for the 
formation of site-specific chemical modifications. Changes to the 
metallopeptide sequence, which altered recognition patterns, 
were found to have a strong effect on catalytic selectivity, and 
could therefore be used to control the chemistry of the 
coordinated xeno-metal complex.[11c] One potential limitation of 
these designs is the use of Glu and Asp residues for Rh(II) 
coordination, which are abundant in proteins and might therefore 
limit the selective introduction of the dirhodium catalyst into more 
complicated peptide assemblies.   
2.4. Ruthenium  
Ruthenium is widely employed in inorganic chemistry, with 
applications including, but not limited to, anticancer drug design, 
catalysis and photochemistry. Two main routes to the synthesis 
of Ru(II) coordinated CCs, involve the introduction of either 1) an 
intact Ru(II) complex, or 2) a non-standard amino acid for 
subsequent Ru(II) coordination (see section 3.2).  
   a)             b) 
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Our first example features the introduction of an intact 
ruthenium complex, for the photochemistry it affords. A 
photolabile biselectrophile Ru(II) complex, Figure 3, that can be 
used for homo- and hetero-dimerization of Cys containing 
peptides, was reported by Mascareñas and co-workers.[12] The 
bromine-functionalized Ru(II) complex was used to assemble 
homo- and hetero- two stranded CCs, based on DNA binding 
bZIP derivatives, reversibly using light.[12]  
Ru
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Figure 3. Structure of the electrophilic Ru(II) linker developed by Mascareñas 
and co-workers.[12] 
Ogawa and co-workers similarly introduced a [Ru(bpy)(phen-
ClA)] complex (where bpy and phen-ClA correspond to 2,2′-
bipyridine and 5-chloroacetamido-1,10-phenanthroline, 
respectively), covalently into a CC by alkylation of a Cys side 
chain.[13] Intriguingly, when the Cys residue was located at the 
helical interface (but not when located on the CC exterior), the 
resulting metallopeptide diastereomers (altered chirality of the 
Ru(II) complex) could be separated by reversed phase-HPLC, 
proposed to be due to the restricted conformational 
environment.[13a] The authors also introduced a pentamine 
ruthenium complex through direct coordination to a His. Using 
these two different approaches the two different ruthenium redox 
active complexes could be selectively introduced at opposite 
ends of the CC. These systems were subsequently used to 
demonstrate that the rate of electron transfer was independent 
of helix dipole direction. 
Further examples of ruthenium complexes introduced by 
complexation with non-proteinogenic amino acids, will be 
discussed in section 3.2. 
 
2.5. Gold 
Auranofin, [AuCl(PEt3)], a drug currently used in the clinic to 
treat rheumatoid arthritis, has shown promising anticancer and 
HIV-activity.[14] The [Au(PEt3)] fragment has been coordinated to 
peptides including a CC, through reaction of [AuCl(PEt3)] with a 
Cys side chain under basic conditions. Coordination was found 
to be reversible with pH, and could represent a potential trigger 
or activation mechanism for the delivery of the potentially active 
[Au(PEt3)]+ species.[15]  
Rather than the introduction of a single metal ion or complex, it 
has also been possible to generate different Au(0) nanoclusters 
within the interior of peptide trimers, tetramers and hexamers.[16] 
These were found to be able to accommodate six, eight and 
twelve Au(I) ions respectively, and on addition of a reducing 
agent, a series of highly stable, photoluminescent Au(0) 
nanoclusters were prepared.[16]  
Finally, CC formation can also be used to assemble Au-
nanoparticles. Two halves of a two-stranded CC, one basic and 
one acidic, were attached to Au-nanoparticles via a terminal Cys. 
CC formation and associated Au-nanoparticle assembly, could 
be controlled under mild conditions. Furthermore, peptide design 
could be used to generate structures with differing stabilities. CC 
assembly could offer a means by which new materials and 
nano-technological devices could be developed.[17]  
 
2.6. Metallo-porphyrins  
DeGrado and co-workers computationally designed 
nanostructure metalloporphyrin arrays of varying length based 
on the α-helical CC motif.[18] Antiparallel tetramer CCs with two 
or four non-biological DPP-Fe(II/III) (DPP = 5,15-di[(4-
carboxymethyleneoxy)phenyl]porphinato) cofactors, were 
designed with specifically placed metalloporphyrins.[18a] The 
variation in length and positioning, allows for the tuning of the 
electrical and optical properties of the porphyrin arrays, and 
these designs were found to display functional redox properties 
previously unobtainable with natural cofactors.[18b]   
The same group also incorporated two xeno iron 
diphenylporphyrins into a transmembrane CC, thereby creating 
a multicentered pathway for transmembrane electron transfer, 
important for photosynthesis and ATP production.[19] The 
designed transmembrane CC scaffold was again used to 
position the redox-active cofactors sufficiently close for electron 
transfer.[19]   
Whilst most metallo-porphyrins contain Fe(II/III), there are 
examples with alternative metals. Four stranded CCs were also 
found to bind Zn(II)-porphyrins[20] in the interior of the scaffold, 
and one example of a Co(II)-porphyrin[21] sees it binding to the 
exterior of the assembly. An advancement in the incorporation of 
porphyrins into peptide scaffolds, saw Fairman and co-workers 
create a system that allows for different metallated porphyrins to 
be incorporated, by taking advantage of non-covalent binding 
between the porphyrin pendant groups and amino acid 
functional groups.[22] An anionic porphyrin, meso-tetrakis(4-
sulfonatophenyl)porphine (TPPS4), was introduced in this way, 
as the conducting material along the CC, through favorable 
electrostatic interactions between Lys side chains and three of 
the four sulfonate groups on the porphyrin.[22]  
The above examples demonstrate how CCs are sophisticated 
scaffolds with which the supramolecular assembly of different 
metalloporphyrins can be achieved in a highly controlled fashion. 
The resulting xeno-porphyrin CCs are promising for the design 
of new photoelectronically active biomaterials.   
3. Non-proteinogenic amino acids 
An important advantage of de novo designed peptides, is that 
they tend to be amenable to solid-phase peptide synthesis 
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(SPPS), which allows for the introduction of non-standard, amino 
acid building blocks. This represents an important opportunity for 
protein engineering, and may provide a mechanism by which 
synthetic biology can surpass natural evolution. Though the use 
of non-proteinogenic amino acids is extensively reviewed 
elsewhere,[5c] of relevance to this focus review are the use of 
non-proteinogenic amino acids in CCs, which either feature 
ligands for metal ions, impact on its coordination chemistry, or 
through which intact complexes can be introduced.  
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Figure 4. Some examples of non-proteinogenic amino acids used in metallo 
CCs; a) γ-carboxy glutamic acid (Gla), b) L-penicillamine (L-Pen), c) residues 
with altered chirality (L- and D-Leu), d) 2-amino-3-(4’-methyl-2,2’-bipyridin-4-yl) 
propanoic acid, and e) (2,2’-bipyridin-5-yl)alanine. 
3.1. Ligands for Ln(III) ions 
As described in section 2.1, a number of designed Ln(III) binding 
sites have employed the non-proteinogenic amino acid, Gla 
(Figure 4a).[7e,8b] Gla can be viewed as a derivative of Glu, which 
contains an additional carboxylate entity, and importantly is 
compatible with CC design, having been successfully introduced 
at both the CC helical interface, and buried within the 
hydrophobic core.[7e,8b] It is due to both its higher charge and 
denticity, that Gla (compared to Glu) binds Ln(III) tightly and 
selectively over Ca(II). The latter being important in view of the 
biological toxicity associated with the majority of free Ln(III) ions.  
With protein structure and folding at the focus of peptide 
design, Samiappan et al.[23] explored the allosteric effects 
associated with CC folding and Ln(III) binding, by introducing 
Ln(III) chelating groups (hydroxyl-pheny oxazoline), either 
through the N-terminus or ε-amine of a lysine (Lys, K) side chain. 
They observed the formation of partially folded trimeric CCs, the 
formation of which induced Ln(III) coordination, which in turn 
yielded a stabilized 3D structure.[23]  
3.2. Heterocyclic derivatives 
Considering the prevalence of 2,2’-bipyridine (bpy) and other 
heterocyclic ligands in ‘traditional’ inorganic chemistry, it is not 
surprising that non-proteinogenic amino acids containing bpy 
side chains, are routinely used for the incorporation of xeno-
metal binding sites within peptide scaffolds.[24] Though biology 
features a heterocycle, His, within its tool-box, the chelating bpy 
can be used to form more stable complexes, and allows one to 
reproduce interesting ‘traditional’ inorganic chemistry complexes. 
Whilst bpy attachment at position 6 leads to steric hindrance and 
poor metal binding,[25] when bound in positions 4 or 5, metal 
binding is readily achieved (Figures 4d and 4e).[26]  
Bpy is a common ligand in ruthenium coordination chemistry, 
and Ru(II) coordination has been used to trigger CC assembly. 
Similar to the Ln(III) induced folding work described in section 
2.1 and 3.1, Ghadiri and co-workers were the first to report how 
a 15 residue peptide with a bpy located at its N-terminus, could 
spontaneously self-assemble in the presence of Ru(II), to yield a 
stable three-stranded CC on formation of a Ru(bpy)3 unit.[27] The 
latter being robust due to the slow ligand exchange kinetics 
associated with Ru(II). 
3.3. Penicillamine and D-amino acids – modification of 
steric bulk 
Pecoraro and co-workers have extensively studied the 
coordination of Cd(II) to thiolate sites engineered into CCs.[28] 
They have also studied the use of non-proteinogenic amino 
acids as a means by which one can control steric bulk, and 
thereby the coordination chemistry and physical properties of 
these sites. For example, replacing L-Cys with L-penicillamine 
(Figure 4b), a bulky analogue with methyl groups in place of the 
β-methylene protons, enhances the bulk around the metal 
centre, to yield a coordinatively unsaturated trigonal planar CdS3 
site (excluding water molecules from coordinating).[29] The same 
result could be achieved by altering the chirality of second 
sphere amino acids (L-Leu vs D-Leu, see Figures 4c and 5), 
reorientating the non-coordinating Leu towards the metal binding 
site and again excluding the coordination of water molecules to 
generate the CdS3 site.[30] These examples demonstrate how 
non-standard amino acids can be used to modify steric bulk, 
when introduced in both a coordinating and non-coordinating 
site within a CC, so as to control metal ion coordination 
chemistry and related properties.  
 
Figure 5. Chemdraw schematic showing the increase in steric bulk around the 
Cys16 residue on mutation of L-Leu12 to the D-Leu12 derivative. © 2008 by 
The National Academy of Sciences, USA.[30]  
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3.4 ‘Click’ chemistry 
‘Click’ chemistry is becoming routinely employed, including in 
the peptide design community, for the covalent linking of two 
units by an easy and efficient reaction, such as the azide alkyne 
Huisgen cycloaddition catalyzed by copper. Not surprisingly non-
proteinogenic amino acids with side chains which feature either 
the alkyne or azide, have been developed for use in SPPS. For 
example, Waters and co-workers introduced Ru(II) and Os(II) 
complexes, covalently linked to the CC via azide-alkyne ‘click’ 
chemistry, at well-defined distances from one another.[31] The 
shape and rigidity of the CC scaffold allowed them to control the 
spatial alignment between the two centers, positioning the 
chromophores for efficient energy transfer, a theme which has 
previously been explored in this focus review[31]  
 
4. Conclusions and perspectives  
Using a de novo or “first-principles” approach to designing 
metallopeptide constructs, is a rapidly developing field, with 
metallo-CCs an attractive intermediary between ‘traditional’ 
small molecule complexes and complex native metallo-proteins. 
Though much effort has been directed towards using this 
approach to develop mimetics of native metallo-protein binding 
sites, here we show the increased interest in the study of xeno-, 
or non-biological, metal binding sites. The resulting xeno 
metallo-CCs can feature examples of non-biological metal ions, 
such as lanthanides, gold and rhodium, in an effort to introduce 
the chemical properties afforded by these metals, or may 
instead harness the control afforded by CC assembly. 
Alternatively, non-proteinogenic amino acid building blocks have 
been introduced, which either feature; non-biological ligands for 
metal ion coordination, so as to be able to generate mimics of 
‘traditional’ small molecule inorganic complexes; chemical 
functionality with which to introduce non-biological metal 
complexes; or altered sterics to control metal ion coordination 
chemistry. As a result of these efforts, xeno metallo-CCs, which 
are beginning to explore the breadth of inorganic chemistry, 
have been reported with a wide range of potential applications, 
ranging from medical imaging, non-biological catalysis and 
photoenergy conversion. Indeed new, currently unforeseen 
applications are likely to come from adopting this approach, and 
this therefore represents an exciting area of metallopeptide 
design. 
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Expanding the bioinorganic chemists toolbox. The use of xeno-metals and non-
proteinogenic amino acids in de novo peptide design, will allow for the assembly of 
new bioinorganic complexes which should combine the advantages of both 
inorganic chemistry and biology into a single hybrid. 
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